Published by
@ShahidNShah
@ShahidNShah
ImmunoPrism platform in well-designed retrospective clinical studies
Cofactor’s ImmunoPrism platform is a solution for uncovering the immune profile of cancer patients. It utilizes RNA from formalin-fixed paraffin-embedded (FFPE) solid tumor specimens and compares it to a database of immune HEMs to quantify key immune signals, including both cells and transcripts. The platform is designed to move beyond single analyte analysis to multidimensional biomarkers, which are generated through machine learning software that identifies the combination of analytes with the highest predictive value. These multidimensional biomarkers are then used to build predictive diagnostics that are deployed in a CAP/CLIA laboratory as a laboratory developed test (LDT). These diagnostics generate a Response Score that predicts a patient’s likelihood of response to therapy and can be used in clinical decision making.
Connecting innovation decision makers to authoritative information, institutions, people and insights.
Medigy accurately delivers healthcare and technology information, news and insight from around the world.
Medigy surfaces the world's best crowdsourced health tech offerings with social interactions and peer reviews.
© 2024 Netspective Media LLC. All Rights Reserved.
Built on Apr 23, 2024 at 3:40am